Related Experiment Video
Updated: Aug 14, 2026

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
Published on: November 3, 2018
No increase in age-specific incidence of myelodysplastic syndromes
Ulrich Germing1, Corinna Strupp, Andrea Kündgen
1Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University of Düsseldorf, Germany. germing@med.uni-duesseldorf.de
Background And Objectives:
Epidemiological data on myelodysplastic syndromes (MDS) are sparse. However, the available evidence indicates that MDS is among the most common hematologic diseases.
Design And Methods:
In a previous study, we showed that incidence rates rose from 1 to 4.1 in the period 1976-1990, with no increase between 1986 and 1990. We extended our study, covering the years 1991 through 2001. Diagnostic criteria and cytomorphology remained the same, consistently applying the criteria of the FAB classification.
Results:
Three-hundred and eight new cases of MDS were identified in the town district of Düsseldorf, which provides the reference population for calculating incidences. There was no further rise in MDS incidence. The crude incidence in the period 1991-2001 was 4.9 (5.52 in males, 4.36 in females), which is similar to that in the 1986-1990 period. Age specific incidences were 8.7, 24.5, and 31.3 for the age groups 60-70, 71-80, and 80-90, respectively. The incidence of MDS in the age group >70 years was significantly higher among males (42.3) than among females (19.0). The preponderance of males was found among patients with refractory anemia with excess blasts (16 vs 3), refractory anemia with excess blasts in transformation (7 vs 2), refractory anemia (15 vs 6) and chronic myelomonocytic leukemia (7 vs 2), whereas, somewhat surprisingly, the age-related incidences refractory anemia with ringed sideroblasts was similar for males and females (4 vs 5). The data on MDS incidence in the town district of Düsseldorf showed a plateau since 1986.
Interpretation And Conclusions:
Interpreting our data covering a 26-year period, we feel that the increase in the early years primarily reflected improved case ascertainment, whereas our new data may provide a good approximation of the true incidence of MDS. There is no evidence that the age-adjusted incidence of MDS is rising.
Insights
The incidence of myelodysplastic syndromes (MDS) has plateaued since 1986, indicating no rise in age-adjusted rates. This suggests improved case ascertainment, not an actual increase in MDS occurrence.
Area of Science:
- Hematology
- Epidemiology
Background:
- Myelodysplastic syndromes (MDS) are common hematologic diseases, but epidemiological data are limited.
- Previous studies indicated a rise in MDS incidence from 1976-1990.
Purpose of the Study:
- To determine the incidence of MDS from 1991-2001.
- To assess trends in MDS incidence over a 26-year period.
Main Methods:
- Analysis of new MDS cases in Düsseldorf from 1991-2001.
- Consistent application of FAB classification diagnostic criteria and cytomorphology.
- Calculation of crude and age-specific incidence rates.
Main Results:
- The crude incidence of MDS from 1991-2001 was 4.9, similar to the 1986-1990 period.
- MDS incidence showed a plateau since 1986.
- Higher incidence observed in males than females, particularly in older age groups and specific MDS subtypes.
Conclusions:
- The initial rise in MDS incidence likely reflected improved case ascertainment.
- Current data suggest a stable, age-adjusted incidence of MDS.
- The findings provide a reliable estimate of true MDS incidence.
Related Concept Videos
Abnormal Proliferation
Meiosis vs. Mitosis
Before the start of mitosis and meiosis I, the cell synthesizes DNA, resulting in two homologous copies of each chromosome. DNA synthesis is...
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Nondisjunction
Cellular Adaptation IV: Dysplasia and Metaplasia

